MedTrace Logo

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

NCT06517953 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-07-25

No results posted yet for this study

Summary

This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.

Conditions

  • Non-small Cell Lung Cancer Metastatic
  • EGFR G719X
  • EGFR L861Q
  • EGFR S768I

Interventions

DRUG

Icotinib

An orally first-generation EGFR inhibitior.

DRUG

Befotertinib

An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-17
Primary Completion
2026-07-30
Completion
2027-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06517953 on ClinicalTrials.gov